Caplin Point gains after USFDA nod for anaesthetic injection

Image
Capital Market
Last Updated : Dec 24 2020 | 12:04 PM IST

Caplin Point Laboratories rose 2.35% to Rs 507.45 after the company said its subsidiary received US drug regulator's approval for etomidate injection USP.

The drug maker said that its subsidiary, Caplin Steriles, received final approval from the United States Food and Drug Administration (US FDA) for its abbreviated new drug application (ANDA) etomidate injection USP, 20 mg/10 ml (2 mg/ml) and 40 mg/20 ml (2 mg/ml) single-dose vial presentations. The product is generic therapeutic equivalent to Amidate (etomidate) injection, of Hospira Inc.

According to IQVIA (IMS Health), etomidate injection USP had US sales data of approximately $9 million for the 12- month period ending Oct 2020.

Etomidate is a general anesthetic, used for the induction of general anesthesia and for the supplementation of sub potent anesthetic agents.

C. C. Paarthipan, chairman of Caplin Point Laboratories, commented: "We understand Etomidate injection has frequently been on the shortage list in the US, which is probably the reason why we received this approval within 6 months. We hope to launch this product within a short period in the US."

Caplin Steriles has developed and filed 19 ANDAs on its own and with partners, with 11 approvals so far.

The company is also working on a portfolio of 35 simple and complex injectable and ophthalmic products, to be filed over the next 4 years, with an addressable market size of $2.1 billion.

Caplin Point Laboratories is a pharmaceutical company. It holds over 2800 product licenses across the globe, with a dominant position in Latin America. The company is entering into Regulated markets of US, EU, Brazil, Mexico, Australia, with a state of the art manufacturing facility for Injectables, already approved by EU-GMP, ANVISA and US FDA.

The pharmaceutical company reported 9.7% increase in consolidated net profit to Rs 62.83 crore on 18% increase in revenue from operations to Rs 268.12 crore in Q2 FY21 over Q2 FY20.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 24 2020 | 11:47 AM IST

Next Story